EUVIMEDEUVIMED entdecken
Crossref

Calming the Storm: Adjunctive Dexmedetomidine for Alcohol Withdrawal Delirium: A Retrospective Comparative Study

Amit Chail, Rishabh Singh, Markanday Sharma

Annals of Indian Psychiatry · 11.07.2026

DOI: 10.4103/aip.aip_313_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Indian Psychiatry, online erschienen am 11.07.2026. Verfasst von Amit Chail und 2 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alcohol Withdrawal Delirium (Delirium Tremens, DT) is a severe and potentially fatal complication of alcohol dependence requiring intensive medical care. Benzodiazepines are the standard treatment, but high doses can cause respiratory depression and may require ventilation. Dexmedetomidine offers sedation without respiratory suppression and can serve as a useful adjunct. We aimed to compare clinical outcomes between patients of Alcohol Withdrawal Delirium receiving standard treatment alone and those receiving adjunctive Dexmedetomidine infusion.

Methods

This retrospective observational study analyzed medical records of patients admitted with Alcohol Withdrawal Delirium between January 2023 and June 2024. Patients were assigned to either: (1) Standard of Care (SOC) with benzodiazepine-based detoxification, or (2) Adjunctive Dexmedetomidine infusion (DEX group). Baseline characteristics and outcomes such as ICU stay duration, benzodiazepine requirements, haloperidol use, and complications were compared.

Results

Outcomes included ICU stay, benzodiazepine and haloperidol use, and complications. Of 44 patients (SOC = 30; DEX = 14), baseline severity was similar. The DEX group showed shorter ICU stay (46.9 vs 52.7 hrs), reduced benzodiazepine duration (10.7 vs 11.5 days) and first-day dose (227 vs 263 mg), and lower PRN haloperidol use (2.7 vs 5.8 mg). Peak agitation (RASS) was lower in DEX (+2.7 vs +3.2). Aspiration pneumonia occurred only in SOC (2 cases).

Conclusion

Adjunctive Dexmedetomidine appears to improve clinical outcomes in Alcohol Withdrawal Delirium by reducing agitation and sedative load without increasing respiratory risk. It represents a useful addition to standard benzodiazepine-based detoxification protocols.

Zitieren

APA

Chail, A., Singh, R., & Sharma, M. (2026). Calming the Storm: Adjunctive Dexmedetomidine for Alcohol Withdrawal Delirium: A Retrospective Comparative Study. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_313_25

Vancouver

Chail A, Singh R, Sharma M. Calming the Storm: Adjunctive Dexmedetomidine for Alcohol Withdrawal Delirium: A Retrospective Comparative Study. Annals of Indian Psychiatry. 2026. doi:10.4103/aip.aip_313_25

BibTeX
@article{Chail2026,
  author = {Chail, Amit and Singh, Rishabh and Sharma, Markanday},
  title = {Calming the Storm: Adjunctive Dexmedetomidine for Alcohol Withdrawal Delirium: A Retrospective Comparative Study},
  journal = {Annals of Indian Psychiatry},
  year = {2026},
  doi = {10.4103/aip.aip_313_25}
}
Kostenlos starten →